Drugs / CimetrA
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT05037162 | Oct 2022 → Jan 2023 | COVID-19 | MGC Pharmaceuticals d.o.o | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04802382 | Jun 2021 → Feb 2023 | COVID-19 | MGC Pharmaceuticals d.o.o | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CimetrA | “CimetrA, comprising Curcumin, Boswellia, and Vitamin C in a nanoparticular formulation, was studied on patients with the novel corona virus SARS-CoV-2 in randomized double...” NCT05037162 ↗ |
| Known as | ArtemiC | “CimetrA, comprising Curcumin, Boswellia, and Vitamin C in a nanoparticular formulation, was studied on patients with the novel corona virus SARS-CoV-2 in randomized double...” NCT05037162 ↗1“CimetrA, comprising Artemisinin, Curcumin, Boswellia, and Vitamin C in a nanoparticular formulation, has been studied on patients with COVID-19 in a randomized double-blind...” NCT04802382 ↗ |
| Known as | CimertrA | “A preparation of CimertrA, comprising Artemisinin, Curcumin, and Boswellia, and Vitamin C in a nanoparticular formulation, is proposed as a treatment for the disease associated...” NCT04802382 ↗ |
| Action | Inhibit | “In the in vitro clinical trial CimetrA demonstrated the ability to reduce cytokines elevation in PBMC induced cell tissue.” NCT05037162 ↗ |
| Route | Other | “in spray administration” NCT04802382 ↗ |